key: cord-0742639-57eff4tj authors: Casavecchia, Grazia; Corbo, Maria Delia; Gravina, Matteo; Barone, Roberta; Magnesa, Michele; Mele, Marco; D'Alessandro, Domenico; Ieva, Riccardo; Iacoviello, Massimo; Macarini, Luca; Brunetti, Natale Daniele title: Arrhythmic myocarditis in an adolescent male: A unique presentation of multi-organ inflammatory syndrome (MIS-C) date: 2022-02-02 journal: Am J Emerg Med DOI: 10.1016/j.ajem.2022.01.061 sha: 31e619df220658f41e998eb41922125c7a3e7006 doc_id: 742639 cord_uid: 57eff4tj Although children with Covid-19 generally present with mild symptoms or are often asymptomatic, there is increasing recognition of a delayed multi-organ inflammatory syndrome (MIS-C) following SARS-CoV-2 infection. We report the case of MIS-C associated arrhythmic myocarditis which recovered after anti-inflammatory therapy and immunoglobulin infusion. The Corona-virus disease (Covid)-19 may present in children with very mild clinical condition and often even as asymptomatic. A possible complication, however, may be represented by an inflammatory delayed syndrome, following the acute phase of SARS-CoV-2 infection by weeks-months, with multi-organ involvement, similar to Kawasaki disease. This SARS-CoV-2 associated Multisystem Inflammatory Syndrome in Children (MIS-C) usually occurs 4-6 weeks after infection and presents with high fever, organ dysfunction, elevated levels of inflammatory markers and signs of shock, in the absence of an alternative explanation (1) . Myocarditis is also possible, with or without signs of coronary arterial inflammation. The pathogenesis is unclear, but some features in overlap with Kawasaki disease (hyperinflammatory syndrome and multiorgan involvement) are suggestive of vasculitis and autoimmune etiology (2) . We report the case of a 15-year-old boy who presented at emergency department for chest pain, relieved by leaning forward, 42 days after SARS-CoV-2 infection. The first antigenic positive test was found on December 23 and confirmed by a molecular test 2 days later; first negative molecular test on January 10. Admission nasopharyngeal swab (molecular test) was negative. Blood pressure was 120/70 mmHg, physical examination unremarkable. Electrocardiogram however showed sinus tachycardia and diffuse ST-elevation (Figure 1 ), QRS amplitude attenuation and prolonged QTc values as for myocardial edema; hs-Troponin-I levels were markedly increased (3652 ng/L, n.v.<20). Basal echocardiography showed preserved global systolic function and minimal pericardial effusion ( Figure 2 ). Chest radiography and blood cell count were normal. The patient was admitted to acute cardiac care unit. After admission, fever appeared (38°C), with abdominal pain and diarrhoea. Abdomen echography was normal. A short run (10 beats) of ventricular tachycardia was also found at continuous electrocardiogram monitoring. In the presence of MIS-C diagnosis (acute myocarditis with intestinal symptoms) intravenous immunoglobulin were infused; after while, a marked improvement of laboratory tests and hs-troponin I levels reduction (5749 ng/L) were observed ( Figure 3 ). Cardiac magnetic resonance showed diffuse signal increase in the left ventricular walls in the sequence T1 Native for the Mapping study (Figure 2a At discharge, the electrocardiogram showed sinus rhythm with negative T-waves and decreased levels of inflammatory markers (CRP) and hs-troponin-I. The boy was discharged 12 days after admission, asymptomatic, with a wearable cardioverter-defibrillator. Echocardiogram, again, was normal. We report the case of MIS-C presenting with myocarditis, ventricular tachycardia and intestinal symptoms. Clinical conditions improved after aspirin therapy and immunoglobulin infusion. Typically, children were less severely affected by SARS-CoV-2 infection than adults (3) (4). The incidence of severe clinical presentation in children varies between 2 and 6%, with a greater risk in patients with previous respiratory, Patients with cardiac involvement could have elevated levels of troponin, BNP, and CK-MB (11) . Given the frequent association of MIS-C with cardiac involvement (over 80%), cardiac testing (echocardiogram, electrocardiogram, J o u r n a l P r e -p r o o f Journal Pre-proof troponin and B-type natriuretic peptide (BNP) or NT-proBNP) must be considered. The cardiac injury involves systodiastolic biventricular dysfunction, mitral regurgitation, arrhythmia and pericardial effusion, while coronary involvement has been described in 6-24% of cases (as mild or as coronary ectasia) (1). Left ventricular systolic dysfunction has been described in most patients affected by MIS-C, from 38% to 100%, with the need for supportive treatments, including ventilatory support, use of inotropes and ECMO (12) . Non-specific electrocardiogram anomalies of the ST segment, prolongation of the QTc segment, atrial and ventricles ectopic beats can be observed in MIS-C, while cases of I-and II-degree atrioventricular block and supraventricular and ventricular arrhythmias are more rare. Serologic testing should be performed prior to intravenous immunoglobulins (IVIG) infusion or any exogenous antibody treatments. The optimal treatment is still not known for a patient with MIS-C; however, a multidisciplinary approach is needed to guide individual treatment, that could be different and is based on the evaluation of symptoms and laboratory values. Patients with MIS-C are usually treated with IVIG, 2 grams/kg (max of 100 grams), by slow infusion (16-24 hours) . Patients have also been treated with steroid therapy (2 to 30 mg/kg/day of methylprednisolone depending on severity of illness) and biologics (13). A recent observational study found that the initial treatment with both IVIG and steroid therapy led to earlier resolution of fever compared to IVIG alone (14) . Antithrombotic prophylaxis should be considered in all MIS-C patients and, unless contraindications, should be started with enoxaparin (15) . Antiplatelet therapy should only be considered if platelet or coronary involvement is present (16) . In our case the therapy was limited to the use of IVIG, after a rapid response to infusion therapy. Noteworthy, we can observe in this case a delayed onset of MIS-C, although previously reported (18), and, given the arrhythmic presentation, a prolonged outpatient monitoring with a wearable ICD in a young boy with myocarditis. None to disclose. COVID-19 and multisystem inflammatory syndrome in children and adolescents. The Lancet. Infectious diseases Hyperinflammatory shock in children during COVID-19 pandemic Epidemiology of COVID-19 among children in China SARS-COV-2 infection in children and newborns: a systematic review Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children US Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 Cytotoxic lymphocytes are dysregulated in multisystem inflammatory syndrome in children. medRxiv The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2 An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort studyexternal icon Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemicexternal icon Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach Children's Hospital in New York City: Patient Characteristics and an Institutional Protocol for Evaluation, Management, and Follow-Up Angoulvant F; French Covid-19 Paediatric Inflammation Consortium. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2